PS128 Successfully Targets Behavioral and Emotional Challenges in Autism Spectrum Disorder (ASD): Completion of Pivotal Clinical Trial on Preschool Children with ASD

PR Newswire | JAN 25, 2024

A recent study published in the Research in Autism Spectrum Disorders unveils groundbreaking solutions for neurodevelopmental disorders. This is the first double-blinded, randomized, placebo-controlled trial aimed at exploring the impact of a single probiotic strain on behavioral changes in preschool children aged 2.5–7 years with autism spectrum disorder (ASD), specifically targeting the gut-brain axis (GBA). Findings from the study provide support for the notion that a brief 2-month intervention with a high dose of PS128 effectively improved certain internalizing issues in young children with ASD.

Read more at: https://www.prnewswire.com/apac/news-releases/ps128-successfully-targets-behavioral-and-emotional-challenges-in-autism-spectrum-disorder-asd-completion-of-pivotal-clinical-trial-on-preschool-children-with-asd-302043964.html